Last updated: 2026-09-16 12:18:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Edesa Biotech, Inc. (EDSA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4,01, with a market capitalisation of $39,87M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,72 to $20,32. This page covers its latest market performance, valuation, price trends and company information.
$39,87M | |
$4,10 | |
$133,70 | |
$0,72 | |
$4,12 | |
2,31K | |
82,12K | |
-- | |
$20,32 | |
$0,72 | |
-- | |
-- |
Edesa Biotech, Inc. (EDSA) is trading at $4,01 in pre-market trading as of 2026-09-16 12:15:00, down 2,65% ($0,11) from the previous close of $4,12
Pre-market trading shows how investors are pricing EDSA before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Edesa Biotech, Inc. (EDSA) moved from $4,73 to $4,01, representing a decline of 15,20% ($0,72).
The stock traded between $4,01 and $5,10 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 36,69 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 16,8%
EDSA is currently trading at $4,01, placing it 16,8% of the way from its 52-week low of $0,72 to its 52-week high of $20,32. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 17 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Edesa Biotech, Inc. (EDSA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.